Nothing Special   »   [go: up one dir, main page]

MX2019012153A - N-ariletil-2-arilquinolina -4-carboxamidas sustituidas y su uso. - Google Patents

N-ariletil-2-arilquinolina -4-carboxamidas sustituidas y su uso.

Info

Publication number
MX2019012153A
MX2019012153A MX2019012153A MX2019012153A MX2019012153A MX 2019012153 A MX2019012153 A MX 2019012153A MX 2019012153 A MX2019012153 A MX 2019012153A MX 2019012153 A MX2019012153 A MX 2019012153A MX 2019012153 A MX2019012153 A MX 2019012153A
Authority
MX
Mexico
Prior art keywords
arylquinoline
arylethyl
substituted
carboxamides
treating
Prior art date
Application number
MX2019012153A
Other languages
English (en)
Inventor
Nagel Jens
Stellfeld Timo
Müller Jörg
Kast Raimund
Terjung Carsten
Anlauf Sonja
Bairlein Michaela
Beck Hartmut
Hauff Peter
Meininghaus Mark
DIETZ Lisa
Dröbner Karoline
Anlahr Johanna
Fürstner Chantal
Von Bühler Clemens-Jeremias
MÜNSTER Uwe
Jörissen Hannah
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of MX2019012153A publication Critical patent/MX2019012153A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente solicitud se refiere a nuevos derivados de N-ariletil-2-arilquinolin-4-carboxamida sustituida, a procesos para la preparación de los mismos, a su uso solo o en combinacionespara el tratamiento o prevención de enfermedades, y al uso de los mismos para la producción de medicamentos para el tratamiento o prevención de enfermedades, especialmente para el tratamiento o prevención de trastornos fibróticos e inflamatorios.
MX2019012153A 2017-04-10 2018-04-04 N-ariletil-2-arilquinolina -4-carboxamidas sustituidas y su uso. MX2019012153A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17165673 2017-04-10
PCT/EP2018/058611 WO2018189011A1 (de) 2017-04-10 2018-04-04 Substituierte n-arylethyl-2-arylchinolin-4-carboxamide und ihre verwendung

Publications (1)

Publication Number Publication Date
MX2019012153A true MX2019012153A (es) 2019-11-21

Family

ID=58530430

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019012153A MX2019012153A (es) 2017-04-10 2018-04-04 N-ariletil-2-arilquinolina -4-carboxamidas sustituidas y su uso.

Country Status (15)

Country Link
US (1) US11136296B2 (es)
EP (1) EP3609869A1 (es)
JP (1) JP7107963B2 (es)
KR (1) KR20190138824A (es)
CN (1) CN110730776A (es)
AU (1) AU2018251758B2 (es)
BR (1) BR112019021136A2 (es)
CA (1) CA3059273A1 (es)
CO (1) CO2019011285A2 (es)
EA (1) EA201992386A1 (es)
IL (1) IL269843B (es)
MX (1) MX2019012153A (es)
PE (1) PE20191616A1 (es)
UA (1) UA125659C2 (es)
WO (1) WO2018189011A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111004170A (zh) * 2019-12-09 2020-04-14 西安近代化学研究所 一种3-氯-5-（三氟甲基）-2-乙胺基吡啶盐酸盐的连续化合成方法

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3738963A1 (de) 1987-11-17 1989-05-24 Bayer Ag 3-aminopyrazolin-5-one
DE69533408T2 (de) * 1994-05-27 2005-09-08 Glaxosmithkline S.P.A. Chinolinderivate als Tachykinin NK3 Rezeptor Antagonisten
IT1270615B (it) 1994-07-14 1997-05-07 Smithkline Beecham Farma Uso di derivati di chinolina
AR004735A1 (es) * 1995-11-24 1999-03-10 Smithkline Beecham Spa Quinoleina 4-amido sustituida, un procedimiento para su preparacion, una composicion farmaceutica que los contiene y el uso de los mismos para lapreparacion de un medicamento.
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
GB9825554D0 (en) 1998-11-20 1999-01-13 Smithkline Beecham Spa Novel Compounds
AU4802500A (en) 1999-04-26 2000-11-10 Neurogen Corporation 2-aminoquinolinecarboxamides: neurokinin receptor ligands
DE19943639A1 (de) 1999-09-13 2001-03-15 Bayer Ag Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943634A1 (de) 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943636A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
AU779442B2 (en) 2000-01-20 2005-01-27 Eisai Co. Ltd. Novel piperidine compounds and drugs containing the same
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
GB0226931D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
WO2006094237A2 (en) 2005-03-03 2006-09-08 Sirtris Pharmaceuticals, Inc. Acridine and quinoline dervatives as sirtuin modulators
CA2757615C (en) 2009-03-31 2018-07-17 Renascience Co., Ltd. Plasminogen activator inhibitor-1 inhibitor
GB2470833B (en) * 2009-06-03 2011-06-01 Amira Pharmaceuticals Inc Polycyclic antagonists of lysophosphatidic acid receptors
TWI503323B (zh) 2010-03-29 2015-10-11 Oncotherapy Science Inc 三環化合物以及含此化合物之ｐｂｋ抑制劑
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
WO2011153553A2 (en) 2010-06-04 2011-12-08 The Regents Of The University Of California Methods and compositions for kinase inhibition
EP2708539A1 (de) 2010-07-09 2014-03-19 Bayer Intellectual Property GmbH Annellierte pyrimidine und triazine und ihre verwendung zur behandlung bzw. prophylaxe von herz-kreislauf-erkrankungen
DE102010040233A1 (de) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclische Aza-Heterocyclen und ihre Verwendung
DE102010043379A1 (de) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung
US20140275224A1 (en) 2010-11-05 2014-09-18 Regents Of The University Of Minnesota Cytosine deaminase modulators for enhancement of dna transfection
EP2684167B1 (en) 2011-03-08 2020-09-09 Eutropics Pharmaceuticals, Inc. Compositions and methods useful for treating diseases
CN104507906B (zh) 2012-05-03 2017-04-12 塔科达有限责任公司 新的ep2受体激动剂
TWI572597B (zh) 2012-06-29 2017-03-01 美國禮來大藥廠 二甲基－苯甲酸化合物
WO2014117090A1 (en) 2013-01-28 2014-07-31 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
CN105793236B (zh) 2013-12-17 2017-10-10 伊莱利利公司 二甲基苯甲酸化合物
WO2016004035A1 (en) 2014-07-01 2016-01-07 Icahn School Of Medicine At Mount Sinai 2-aryl-4-quinolinecarboxamide derivatives for treating thyroid diseases
WO2016037954A1 (de) 2014-09-09 2016-03-17 Bayer Pharma Aktiengesellschaft Substituierte n,2-diarylchinolin-4-carboxamide und ihre anti-inflammatorische verwendung
CN107427506A (zh) 2014-10-14 2017-12-01 拉霍拉敏感及免疫学研究所 低分子量蛋白酪氨酸磷酸酶的抑制剂及其用途
EP3229801B1 (en) 2014-12-10 2020-04-01 Merck Sharp & Dohme Corp. Factor ixa inhibitors
EP3271334A1 (de) 2015-03-18 2018-01-24 Bayer Pharma Aktiengesellschaft Substituierte n-bicyclo-2-arylchinolin-4-carboxamide und ihre verwendung

Also Published As

Publication number Publication date
KR20190138824A (ko) 2019-12-16
PE20191616A1 (es) 2019-11-05
EP3609869A1 (de) 2020-02-19
CA3059273A1 (en) 2018-10-18
AU2018251758B2 (en) 2021-11-18
EA201992386A1 (ru) 2020-03-27
AU2018251758A1 (en) 2019-10-24
IL269843B (en) 2022-04-01
WO2018189011A1 (de) 2018-10-18
CN110730776A (zh) 2020-01-24
JP2020513025A (ja) 2020-04-30
US11136296B2 (en) 2021-10-05
UA125659C2 (uk) 2022-05-11
CO2019011285A2 (es) 2019-10-31
BR112019021136A2 (pt) 2020-07-21
JP7107963B2 (ja) 2022-07-27
US20200031775A1 (en) 2020-01-30
IL269843A (en) 2019-11-28

Similar Documents

Publication Publication Date Title
PH12018500057A1 (en) Substituted oxopyridine derivatives
MX2022007989A (es) Composiciones y metodos para tratar pterigion.
PT3377637T (pt) Composições para uso em métodos para o tratamento de ferimentos, transtornos e doenças da pele
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
PH12016502015A1 (en) Anti-factor d antibody variants and uses thereof
PH12019502315A1 (en) Substituted n-arylethyl-2-aminoquinoline-4-carboxamides and use thereof
MX2020005567A (es) Metodos de tratamiento con asparaginasa.
WO2019040106A3 (en) COMPOUNDS, RELATED SALTS AND METHODS FOR THE TREATMENT OF DISEASES
WO2016077639A3 (en) Nanovesicular therapies
MX2017009417A (es) Formas solidas de acido 2-(5-(3-fluorofenil)-3-hidroxipicolinamido )acetico, composiciones y usos de las mismas.
MX2016000258A (es) Bencil-1h-pirazolo[3,4-b]piridinas y su uso.
MA39710A (fr) Composition topique destinée à être utilisée dans le traitement d'une maladie inflammatoire de l'intestin
MX2018008644A (es) Derivados de 3-((hetero)aril)-alquil-8-amino-2-oxo-1,3-diaza-espir o-[4.5]-decano.
MX2018008645A (es) Derivados de 8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano.
PH12016500525A1 (en) Substituted phenylalanine derivatives
PH12016501371A1 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
MX2018008643A (es) Derivados de 3-((hetero)aril)-8-amino-2-oxo-1,3-diaza-espiro-[4.5] -decano.
MX2018008640A (es) Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]- decano.
MX2017014456A (es) Usos terapeuticos de l-4-cloroquinurenina.
PH12019500535A1 (en) 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof
MX2018009662A (es) Metodo y composicion farmaceutica para tratamiento de neurodegeneracion.
MX2019000677A (es) Células miméticas de células b.
MX2020001256A (es) Compuestos para la prevencion y el tratamiento de trastornos medicos y usos de los mismos.
MX2017004723A (es) Composicion farmaceutica para usarse en el tratamiento o la prevencion de deficiencias de vitaminas y minerales en pacientes que han sido sometidos a cirugia de derivacion gastrica.
MX2019012153A (es) N-ariletil-2-arilquinolina -4-carboxamidas sustituidas y su uso.